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Abstract
Sex-differences in human liver gene expression were characterized on a genome-wide scale using a large liver sample
collection, allowing for detection of small expression differences with high statistical power. 1,249 sex-biased genes were
identified, 70% showing higher expression in females. Chromosomal bias was apparent, with female-biased genes enriched
on chrX and male-biased genes enriched on chrY and chr19, where 11 male-biased zinc-finger KRAB-repressor domain
genes are distributed in six clusters. Top biological functions and diseases significantly enriched in sex-biased genes include
transcription, chromatin organization and modification, sexual reproduction, lipid metabolism and cardiovascular disease.
Notably, sex-biased genes are enriched at loci associated with polygenic dyslipidemia and coronary artery disease in
genome-wide association studies. Moreover, of the 8 sex-biased genes at these loci, 4 have been directly linked to
monogenic disorders of lipid metabolism and show an expression profile in females (elevated expression of ABCA1, APOA5
and LDLR; reduced expression of LIPC) that is consistent with the lower female risk of coronary artery disease. Female-biased
expression was also observed for CYP7A1, which is activated by drugs used to treat hypercholesterolemia. Several sex-
biased drug-metabolizing enzyme genes were identified, including members of the CYP, UGT, GPX and ALDH families. Half of
879 mouse orthologs, including many genes of lipid metabolism and homeostasis, show growth hormone-regulated sex-
biased expression in mouse liver, suggesting growth hormone might play a similar regulatory role in human liver. Finally,
the evolutionary rate of protein coding regions for human-mouse orthologs, revealed by dN/dS ratio, is significantly higher
for genes showing the same sex-bias in both species than for non-sex-biased genes. These findings establish that human
hepatic sex differences are widespread and affect diverse cell metabolic processes, and may help explain sex differences in
lipid profiles associated with sex differential risk of coronary artery disease.
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Introduction
Mammalian sex determination is initiated by the SRY gene,
which activates a developmental pathway leading to testis
formation and establishes life-long sex differences in the patterns
of gonadal hormone secretion [1]. Gonadal hormones, in turn,
exert permanent differentiating effects (‘organizational’ actions) as
well as short-term stimulatory effects that lead to sex differences in
gene expression in multiple tissues [2]. Sex differences are also
induced by non-gonadal signals and factors, including direct sex-
biased effects of individual X and Y-chromosome genes [3].
Epigenetic modifications also play an important role in the
development and maintenance of sexual dimorphism [4] by
processes such as genetic imprinting [5,6] and X-chromosome
inactivation [7,8,9]. Sex differences characterize histone acetyla-
tion and histone methylation [10] and the expression of certain
histone demethylases [11,12]. Sexual differentiation is thus
achieved through a complex interplay of multiple mechanisms
[13].
Global gene expression studies in mouse and rat liver have
identified .1,000 sex-dependent transcripts, which collectively
have a major impact on hepatic physiology, inflammatory
responses, diseased states, and the metabolism of steroids, drugs
and environmental chemicals [14,15,16]. However, very little is
known about the sex-dependence of gene expression in human
liver. Small but pharmacologically significant sex differences in the
expression of certain human hepatic drug-metabolizing CYP
enzymes have been reported, most notably for CYP3A4 [17,18],
however, only limited efforts have been made to identify sex
differences in human liver on a larger scale [19]. Such studies have
the potential to elucidate clinically important sex differences in
human hepatic physiology and pathophysiology, including sex
differences in circulating lipid profiles, which are more favorable in
women [20,21] and are associated with their lower risk of
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wide association studies (GWAS) identified 22 loci associated with
sex-biased serum lipid phenotypes [24], however, it is not known
whether sex differences characterize gene expression from these or
other loci contributing to lipid metabolism.
The present study was undertaken to characterize sex
differences in human liver on a genome-wide scale using a large
liver sample collection, which allows for detection of small
expression differences with high statistical power. Using this
approach, we identify 1,249 genes that show significant sex
differences in expression, 70% of which are more highly expressed
in females. We show that hepatic sex-biased genes are enriched in
functions related to transcription, chromosome organization and
sexual reproduction, among others. Furthermore, we report that
sex-biased gene expression is most significantly associated with
genes that participate in or regulate lipid metabolism, several of
which have previously been associated with polygenic dyslipidemia
and cardiovascular disease in GWAS analyses or are established
drug targets for treatment of hyperlipidemia and hypercholester-
olemia. We also report that half of the mouse orthologs of sex-
biased human hepatic genes, in particular those involved in lipid
metabolism and homeostasis, show sex-biased expression in mouse
liver, where growth hormone (GH) is the major regulator of sex
differences, and that genes that show the same sex bias in human
and mouse liver have evolved more rapidly than non-sex-biased
genes. These latter findings provide insight into species similarities,
as well as species differences, in liver sex specificity.
Methods
Ethics Statement
The study was approved by the ethics committees of the medical
faculties of the Charite ´, Humboldt University Berlin and the
University of Tuebingen, and the institutional review board of
Boston University, and was conducted in accordance with the
Declaration of Helsinki. Written informed consent was obtained
from each patient.
Human liver panel
Human liver samples (112 male samples, 112 female samples;
German residents of white ethnicity) were obtained from patients
undergoing liver surgery at the Department of General, Visceral
and Transplantation Surgery (Nuessler AK and Neuhaus P,
Campus Virchow, University Medical Center Charite ´, Humbold
University in Berlin, Germany). The average age of the subjects
was 55.8613.3 yr (males) and 55.5614.7 yr (females) (Table S1A).
Subjects had undergone surgery to have primary or metastatic
liver tumors removed, or had hepatic tissue resected for other
reasons. Only non-tumorous liver tissue was collected, and the
absence of tumorous material was confirmed for all samples by
histochemical analysis. Livers from donors with severe liver disease
(viral hepatitis, human immunodeficiency virus, cirrhosis) or
chronic alcoholism were excluded from the study. For additional
information see Table S1A. Additional information is provided
elsewhere [25] for 150 of the livers used in the present study. Liver
tissue was stored at 280uC.
RNA processing and microarray analysis
RNA was isolated from liver tissue by Trizol extraction and
Qiagen RNeasy-Mini Kit with on-column DNase treatment [26].
Only high quality RNA preparations were used in this study, as
determined by Agilent Bioanalyzer (RIN value .7 using Agilent
Nano-Lab Chip Kit; Agilent Technologies, Waldbronn, Ger-
many). A first set of randomized liver RNA pools was generated by
randomly distributing the 112 male and 112 female liver RNA
samples into 8 pools comprised of 14 male liver samples each
(pools M1 to M8) and 8 pools of 14 female liver samples each
(pools F1 to F8). Each pool was prepared by combining 0.5 mg
total RNA from each of the 14 livers in the pool, to give 7 mg RNA
in a final volume of 30 ml. The final RNA concentration was
determined by Nanodrop analysis (Thermo Fisher Scientific Inc.,
Waltham, MA). A second set of 16 pools was prepared from the
same set of 224 liver samples in the same way (male pools M9 to
M16 and female pools F9 to F16) (Table S1B).
The 16 liver RNA pools of each sex were used in a total of 16
two-color, male vs. female hybridization microarrays by pairing
pool M1 with pool F1, pool M2 with pool F2, etc. Fluorescent
labeling of RNA and hybridization of the Alexa 555-labeled and
Alexa 647-labeled amplified RNA samples to Agilent Whole
Human Genome oligonucleotide microarrays (4644K format;
Agilent Technology, Palo Alto, CA; catalog # G4112F) was
carried out, with dye swaps to eliminate dye bias [27,28]. TIFF
images of each scanned slide were analyzed using Agilent’s feature
extraction software followed by linear and LOWESS normaliza-
tion and initial data analysis using Rosetta Resolver (version 5.1,
Rosetta Biosoftware, Seattle, WA) [29]. The full set of normalized
expression ratios and p-values is available at the Gene Expression
Omnibus web site (http://www.ncbi.nlm.nih.gov/geo) as GEO
series GSE23766.
Microarray annotation and data analysis
41,000 probe sequences (60 nt long) provided by Agilent were
mapped to the hg19 human genome using BLAT [30]. Probes
with at least 56 nt sequence overlap with the genomic coordinates
of hg19 or with GeneBank mRNAs were assigned the indicated
annotation. Where available, RefSeq annotations were assigned to
each probe as the highest priority, followed by non-RefSeq
mRNA, then Ensembl, spliced EST, and finally unspliced ESTs
annotations in order of decreasing priority. When two or more
probes mapping to the same gene name showed the same sex-bias,
only the probe with the highest composite array score (defined
below) was retained. Probes associated with the same gene name
but different sex-bias were retained, resulting in 33,250 non-
redundant probes.
The fold-change was defined as the normalized male/female
expression ratio for ratios .1, and as the negative inverse of the
normalized male/female expression ratio for ratios ,1. For each
probe, a mean fold-change and p-value was calculated based on
the set of 16 microarray expression ratios using the Rosetta
Resolver-based error model [29]. The error model uses technol-
ogy-specific data parameters to stabilize intensity variation
estimates, along with error-weighted averaging of replicates. This
approach has been demonstrated to provide an effective increase
in statistical power [29]. In the present study, the mean standard
deviation of log10 ratios for the 16 replicate arrays was 0.0896;
power analysis based on this variance indicated that a fold change
of 1.17 can be detected with a power of 0.8 (80%). A composite
array score, ranging from 8–16, was also determined based on the
number of arrays out of 16 that showed agreement with respect to
whether the corresponding gene (i.e., transcript) was expressed at a
higher level in the male liver pool (fold-change.1; male-biased
expression) or at a higher level in the female liver pool (fold-
change,21; female-biased expression). A total of 1,249 probes
(genes), listed in Table S2A, showed sex-biased expression with
high stringency based on a combination of the following three
criteria: mean |fold change| between male and female liver
.1.15, p-value,0.005, and composite array score $14. This list
of 1,249 sex-biased genes eliminates 13 probes that did not match
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but could not be mapped to any GeneBank mRNAs. 33 other
probes met the |fold change| and the composite array score
criteria but not the p-value threshold and were excluded, to
eliminate probes with high variance in fold-change.
An apparent false discovery rate (FDR) was calculated as
follows: of the 33,250 non-redundant probes, 4,734 had a mean
|fold change|.1.15. The number of probes expected to meet the
fold-change and composite array score k$14 by chance is:
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The actual number of probes that passed the combination
threshold was 1,295, corresponding to an apparent FDR of 10/
1295, or 0.77%. In an alternative approach to calculating the
FDR, a p-value,0.005 was applied to the 4,734 probes that
exhibited a |fold change|.1.15, resulting in 4,734 * 0.005=24
probes expected to meet the combined criteria, whereas 2,575
probes actually passed this combined threshold, corresponding to
an apparent FDR of 24/2575=0.93%. Finally, given our rigorous
experimental design and the Rosetta error model, the FDR
remains very low even when applying statistical tests to the entire
probe set. Thus, applying a p-value cutoff of 0.005 to all 41,000
probes on the microarray, 6,902 probes were identified as showing
statistically significant sex differences, as compared to 41,000 *
0.005=205 probes that are expected to be identified by chance,
corresponding to an FDR of 205/6,902=3%.
Where indicated, the composite array score filter was relaxed to
$13 (1,855 probes) or to $12 (2,303 probes) to test the robustness
of conclusions drawn from the most stringent cutoff (composite
array score $14, |fold change|.1.15 and p,0.005). Table S2A
and Table S2B present the gene lists, fold-changes, p-values and
composite scores at all three levels of significance. Chi-square test
was used to test the significance of apparent differences in sex-
biased gene distributions across chromosomes. These analyses
were carried out using sets of sex-biased genes determined at three
levels of significance, namely, composite array score .14, 13 and
12, respectively, all combined with p-value,0.005 and |fold-
change|.1.15. Only those genes whose microarray probes
showed a single hit across the genome based on BLAT analysis
[30] were used for chromosome mapping analysis, including
analysis of the distribution of sex-biased genes on chromosome 19
and the sex-chromosomes.
Hierarchical clustering and heat map generation were carried
out using Cluster [31] and Java Treeview [32], respectively.
Enrichment of Gene Ontology, protein domain, pathway, and
functional categories was determined using DAVID (http://david.
abcc.ncifcrf.gov). The Core Analysis function of Ingenuity
Pathway Analysis (Ingenuity System Inc, USA) was used to
identify biological functions, pathways and networks associated
with the 1,249 sex-biased genes. To examine the sex-dependent
expression of genes related to ADME (absorption, distribution,
metabolism and excretion), we used a list of 300 ADME genes
(http://pharmaadme.org/) supplemented by 71 ADME-related
genes from http://pharmaadme.org/ and 42 genes comprised of
members of the CYP, FMO, UGT, SULT, GST, NAT, ADH, ALDH
and ARS gene families not represented in the 300 ADME or 71
ADME-related lists.
Comparison to 465 human liver microarray dataset
Validation of microarray results was carried out using an
independent cohort of 465 human livers (253 males and 212
females) based on microarray analysis and annotations reported by
Schadt et al. [33] with expression data and sex identifiers
downloaded from http://sage.fhcrc.org/downloads/downloads.
php. The dataset represents mostly post-mortem liver samples,
primarily from Caucasian individuals, who were prospective organ
donors and were obtained from three independent tissue resource
centers, at Vanderbilt University, University of Pittsburgh, and
Merck Research Laboratories. This 465 liver dataset includes 757
RefSeq genes in common with the 1,019 sex-biased RefSeq genes
identified in this study based on our 224 liver dataset (Table S2).
The ratio of average male expression to average female expression
was calculated across the full set of 465 liver samples for all 757
genes, and a two-tail t-test p-value was determined for the resultant
set of male to female expression ratios. For genes represented by
duplicate microarray probes, only the probe with the lowest p-
value was kept. Four of the 757 genes (DAZ2, ZFY, DDX3Y/
DDX3X, LRRC6) showed large differences in sex ratio between the
two studies and were excluded from further analysis, leaving 753
genes; these include 195 male-biased genes and 558 female-biased
genes. DAZ2 and ZFY are Y-chromosome genes that showed the
expected high male/female ratio in our array dataset (ratios of 14
and 59, respectively) but not in the 465 liver dataset (male/female
ratios of 1.2 and 0.53, respectively) suggesting cross hybridization
to non-Y chromosome sequences. DDX3Y/DDX3X showed strong
(16-fold) male-biased expression in the 465 liver dataset, but only
1.66-fold male bias in our dataset, while LRRC6, characterized as a
testis-specific gene, showed 1.22-fold male-biased expression in our
dataset, but strong (4.0-fold) female-biased expression in the 465
liver dataset. Gene Set Enrichment Analysis (GSEA; www.
broadinstitute.org/gsea/) was used to compare the overall profile
of sex-biased genes in our 224 liver dataset to that of the 465 liver
dataset. 20,415 of the 40,638 microarray probes in the 465 liver
dataset have RefSeq gene symbols in common with our
microarray platform; 7,061 of these probes represent duplicated
gene symbols and were removed, leaving 13,324 probes (probes
having the lowest male/female t-test-based p-value were retained).
Expression data for all 465 livers for the 13,354 RefSeq probes was
used as input for GSEA and compared to the above set of 195
male-biased genes, and separately, to the set of 558 female-biased
genes identified from the 224 liver dataset.
Pearson correlation was calculated between the sets of male/
female expression log2-ratios determined for our 224 liver dataset
and the 465 liver set. Permutation analysis was used to determine
the significance of the correlation coefficient between each dataset,
as follows. 16 male and 16 female liver samples (equal to the
number of liver sample pools analyzed on our arrays) were
randomly selected from the set of 465 liver samples, and male/
female expression ratios were calculated for the 753 common
genes specified above. A second male/female ratio was calculated
for the remaining 433 liver samples. The Pearson correlation
coefficient was recorded, and the procedure was repeated 1,000
times, giving 1,000 correlation coefficients. In other analyses,
male/female expression ratios were calculated for subsets of the
465 liver set, comprised of individuals aged 15–52 (216 liver
samples) and individuals aged 58 and older (165 liver samples). A
Pearson correlation coefficient of 0.52 was calculated for the two
sets of log2-ratios of the two age-determined liver subsets; this
correlation is not significantly lower than the mean correlation
coefficient of 0.57 determined for the full set of 465 livers by
random permutation of 100 pairs of liver samples from the 465
liver study, indicating age does not have a significant effect of sex-
biased liver gene expression. In addition, Pearson correlation
coefficients=0.58 and 0.59, respectively, were determined when
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of the two age-based subsets of the 465 liver dataset.
Comparison to sex-biased genes in mouse and rat liver
and analysis of non-synonymous versus synonymous
substitution rates (dN/dS)
Orthologous gene pairs obtained from the mammalian
orthology section of the Mouse Genome Informatics website, at
http://www.informatics.jax.org/orthology.shtml, were used to
identify mouse and rat orthologs of the human sex-biased genes
that show sex-dependent expression in mouse or rat liver based on
our earlier microarray studies; those studies used an Agilent mouse
[27,28] and an Agilent rat microarray platform [14], and a mouse
microarray platform developed for Merck, Inc. [15,34]. All non-
duplicated genes that met the criteria of |fold change|.1.15 in
combination with either p,0.005 (mouse Agilent platform) or
p,0.05 (mouse Merck platform and rat Agilent platform) in at
least one of the earlier studies were selected. The impact of
hypophysectomy on the expression of mouse and rat liver sex-
biased genes was based on our published data [14,28]. The
program codeml implemented in the PAML software package [35]
was used to calculate the dN/dS ratio for human-mouse or
human-rat orthologous gene pairs using the maximum-likelihood
method [36]. When several gene accessions mapped to a given
gene symbol, ratios of all accessions were calculated and the
median dN/dS ratio was used. Non-sex-biased genes expressed in
liver were identified based on these criteria: microarray signal
intensity .100 in human liver; and |fold-change|,1.01 in both
human and mouse (or rat) expression microarrays [14,28]. 800
and 701 non-sex-biased human-mouse and human-rat ortholo-
gous were identified. Permutation testing was used to evaluate the
difference between two medians. Specifically, we randomly
selected two orthologous gene sets (each containing the same
number of genes as the sets to be tested) and calculated the
difference of the median, repeating the permutation 10,000 times.
The number of times that the difference of the randomly selected
group was higher than the observed difference was recorded as
Nd. The permutation p-value was defined as Nd/10,000.
Results
Genes showing sex-biased expression in human liver
Human liver RNA was isolated from 112 male and 112 female
livers, from which 16 male liver RNA pools and 16 female liver
RNA pools were prepared and analyzed on two-color microarrays.
1,249 genes (transcripts) showing sex differences (sex bias) in
expression were identified based on a combination of three
criteria: mean |fold change| between male and female liver
.1.15, p-value,0.005, and composite array score $14, with an
apparent FDR,1% (see Methods). 873 of the 1,249 genes (70%)
were expressed at a higher level in female liver and 376 genes
(30%) were expressed at a higher level in male liver (Table S2A).
Analysis of the chromosomal distribution of genes showing sex-
biased expression (Figure 1A; also see Figure S1 and Figure S2)
revealed the highest male/female ratio for Y-chromosome genes,
consistent with the sex assignments of the livers. The expressed Y-
chromosome genes include USP9Y, a deubiquitination enzyme
required for spermatogenesis, non-coding RNA transcripts such as
TTTY15, and the JMJC domain histone demethylases UTY and
KDM5D. 36 female-biased genes and 5 male-biased genes were
found on the X-chromosome (Table 1, Table S2A and Figure
S1B). These genes include zinc finger proteins (ZFX, KDM5C,
PHF6, MBNL3, ZMAT1), transmembrane proteins (IL1RAPL1,
STS, EDA, GPR82, GJB1, PGRMC1), and JMJC domain histone
demethylases (KDM6A, KDM5C).
Partial escape from X-chromosome inactivation in
human liver
Female-biased genes were enriched on the X-chromosome
(p,0.001), which may reflect incomplete X-chromosome dosage
compensation, whereby one X-chromosome is generally silenced
(inactivated) in female cells [7,8,9]. XIST, an X-linked non-coding
RNA gene that is a major effector of X-inactivation [37], showed
the highest female/male expression ratio in our microarrays
(Table 1). In a study using mouse/human hybrid cell lines that
retain an inactive human X-chromosome, ,15% of X-linked
genes were found to be expressed from both X-chromosomes (i.e.,
escape or partially escape X-inactivation) [8], whereas only ,5%
of X-linked genes had this property in a study based on a panel of
human lymphoblastoid cell lines [7]. Presently, we found that 4–
6% of X-chromosome genes showed female-biased expression in
liver (36, 44, and 50 X-linked genes, when assessed at composite
array scores $14, $13, and $12, respectively; Figure 1A, Figure
S2 and Table S2A, B). Furthermore, 10 of the 15 X-chromosome
genes that showed consistent escape from X-inactivation in the
human lymphoblastoid cell line study [7] showed consistent
female-biased expression in human liver (composite array
score=16; Table 2), suggesting they escape X-inactivation in
human liver as well. Indeed, all but two of the X-chromosome
genes (PGRMC1, PHF6; Table 1) that showed female-biased
expression in human liver also show female-bias in human muscle
[38], supporting the conclusion that the female-biased expression
of these genes reflects (partial) escape from X-inactivation, rather
than hormone-based sex-bias or other mechanisms. In another
study, 13 of 393 X-linked genes expressed in a female mouse
kidney cell line escaped X-inactivation [39]. 11 of these 13 genes
have corresponding human transcripts, 5 of which also showed
female-biased expression in liver in all 16 arrays (XIST, KDM6A,
DDX3X, KDM5C, CXORF38), suggesting they also escape X-
inactivation in human liver.
Enrichment of male-biased genes on chromosome 19
Female-biased genes predominate on all autosomes except
chromosome 19, where male-biased genes are significantly
enriched (Figure 1A and Table 3; p=2.7E-15 when compared
to the overall distribution of sex-biased genes across the genome;
see Methods). This same pattern characterized sex-biased genes
identified at two lower levels of significance (composite array score
.13 and composite array score .12, combined with |fold
change|.1.15 and p-value,0.005; see Methods) (Figure S2). 16 of
the 40 sex-biased genes on chromosome 19 are associated with
transcription, and 13 are ZNF (zinc finger protein) transcription
factors that map to six established ZNF clusters (Figure 1B) [40].
An additional 6 ZNF genes on chromosome 19 show sex-biased
expression at a lower stringency (composite array score $13;
Table S2C), and overall, 16 of the 19 sex-biased ZNF genes on
chromosome 19 show higher expression in males.
Functional analysis of human hepatic sex-biased genes
Functional clustering enrichment analysis [41,42] revealed
enrichment of female-biased genes in transcription and chromatin
remodeling and epigenetic modification, pattern specification,
cytoskeleton organization, cell junction and cell projection (Figure
S3A), whereas male-biased genes are enriched in processes related
to sexual reproduction (Figure S3B). Further details of the
enriched functional clusters are provided in Table S3A. 277 of
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(Table S3A) and 158 are involved in transcription regulation
(Table S2D). Transcription factors showing sex-biased expression
include 69 ZNFs, 9 homeo-box genes (female-biased HOXB3,
HOXD11, LHX2, ONECUT1, ONECUT2 and ZEB1; and male-
biased CUX2, IRX3 and PBX1), and 6 female-biased nuclear
receptors (HNF4A, NR2C2, NR2F2, PGR, PPARA, RORA). 45 sex-
biased genes are significantly associated with chromatin organiza-
tion and modification as determined by enrichment analysis
(Figure 2, Table S2E, and Table S3A). These include 5 female-
biased histone genes (HIST1H4B, HIST1H4C, HIST1H4D,
HIST1H4J, HIST1H4L), 5 female-biased histone methyltransfer-
ase genes (ASH1L, MLL, MLL3, MLL5, SETD2), and one male-
biased histone methyltransferase (DOT1L). Sex-biased genes
containing JMJ domains with potential histone demethylase
activity include JMJD1C, JMJD5, KDM4A, KDM5B, KDM5C,
KDM6A (female-predominant) and KDM4C, KDM5D and UTY
(male-predominant). Other sex-biased genes include a female-
predominant histone deacetyltransferase (HDAC9) and several
histone acetyltransferases (CREBBP, EP300, MYST4, NCOA3).
Sex differences in lipid and drug metabolism
Lipid metabolism was identified as the top molecular and
cellular function significantly affected by the sex-biased genes
Figure 1. Chromosomal distribution of male-biased and female-biased genes identified in human liver. (A) Number of male- and
female-biased genes on each chromosome, based on the criteria |fold change|$1.15 and composite array score $14. Numbers at the top of each bar
indicate the ratio of the number of female-biased genes to male-biased genes on each chromosome. Asterisks indicate the significance of the sex
ratio based on Chi-square tests (*p,0.05; **p,0.01; ***p,0.001; red asterisks indicate significant enrichment of female-biased genes and blue
asterisks indicate significant enrichment of male-biased genes). (B) Log2 male/female expression ratios for sex-biased genes on chromosome 19 vs.
chromosomal location, based on genome release hg18. Blue bars at the bottom mark six previously defined ZNF gene clusters [40] that contain 13
sex-biased ZNFs in human liver; these ZNF genes show an enrichment score of ,2.0 relative to the total number of ZNF genes on chromosome 19. An
additional 6 sex-biased ZNF genes with a composite array score of 13 (Table S2C) are included, and marked with gene names shown in blue.
doi:10.1371/journal.pone.0023506.g001
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fatty acid, cholesterol and triglyceride metabolism, encompassed
62 female-biased genes and 19 male-biased genes (Figure 3A,
Table S2F and Table S3B). Top networks associated with these 81
genes include lipid metabolism, molecular transport and small
molecule biochemistry (Figure 3B).
Cardiovascular disease is the most significant disease associated
with sex-differential gene expression, and includes 185 sex-biased
genes (Table 4A, Table S2G and Table S4A). Since dyslipidemia is
a key risk factor for heart disease, we calculated the overlap and
determined that 28 of the 81 sex-biased, lipid metabolism-related
genes have previously been associated with cardiovascular disease
(Table S2F). Moreover, 7 female-biased genes (ABCA1, APOA4,
APOA5, APOC4, DOCK7, HNF4A, LDLR) and 3 male-biased genes
(ANGPTL4, LIPC, PSRC1) are adjacent to a subset of the 30 loci
previously associated with circulating concentrations of low density
lipoprotein (LDL)-cholesterol, high density lipoprotein (HDL)-
cholesterol and triglycerides and polygenic dyslipidemia by GWAS
analysis [43,44], with enrichment p-values ranging from 3E-9 to
5E-6 (Figure 3A, Table S2F and Table S3B). Furthermore, 8 of
these 10 genes (all except HNF4A and ANGPTL4) are near 20 loci
that influence lipid concentrations and risk of coronary artery
disease [24,45] (Figure 3A, Table S2F and Table S3B).
The liver is the major site of drug clearance, and it expresses
numerous drug-metabolizing enzymes belonging to the CYP, UGT,
GPX, ALDH and other gene families. To fully evaluate the extent
of sex-differences in drug-metabolizing enzyme expression and
related processes, microarray data for 413 ADME and ADME-
related genes were examined. We identified 30 ADME/ADME-
related genes that show significant sex differences in expression at
a composite array score $14 (Figure 4), and an additional 10
genes were identified when the composite array score was relaxed
to 13 (Table S2H).
Validation of key findings using a second liver cohort
To validate our microarray data, we examined an expression
microarray dataset based of 465 individual human livers [33]. Of
the 1,019 sex-biased RefSeq genes identified in our 224 liver
dataset, 753 were represented in the 465 liver array dataset; these
include 195 male-biased genes and 558 female-biased genes (see
Methods). Comparison of the overall pattern of sex-biased genes
between the two liver datasets by GSEA showed that the 195
Table 1. Sex-biased genes on sex chromosomes (fold-change.|1.15| and composite array score $14).
Gene Symbol Gene Accession
Fold-Change (F,0;
M.0) Gene Symbol Gene Accession
Fold-Change
(F,0; M.0)
X-chromosome
XIST NR_001564 224.12 MBNL3 NM_133486 21.29
FRMD7 NM_194277 22.53 GPR82 NM_080817 21.25
ZFX NM_003410 21.89 SMC1A NM_006306 21.25
IL1RAPL1 AJ243874 21.86 RIBC1 NM_001031745 21.24
PNPLA4 NM_004650 21.71 - ENST_00000436419 21.22
KDM6A NM_021140 21.66 TTC3L NR_030737 21.21
HDHD1A NM_012080 21.62 CXorf15 NM_018360 21.21
GYG2 NM_003918 21.57 LOC644538 NM_001163438 21.20
STS NM_000351 21.53 FMR1 NM_002024 21.19
ENOX2 NM_182314 21.48 ZMAT1 NM_032441 21.19
EIF1AX NM_001412 21.46 OPHN1 NM_002547 21.18
CHM NM_000390 21.43 PGRMC1 NM_006667 21.17
EDA NM_001399 21.42 DDX3X NM_001356 21.16
KDM5C NM_004187 21.41 GJB1 NM_001097642 21.16
MUM1L1 NM_152423 21.38 STAG2 NM_006603 21.15
- AK022479 21.37 NXF3 NM_022052 1.19
CXorf38 NM_144970 21.35 - AK124653 1.29
MAP7D3 NM_024597 21.34 - AK123627 1.30
VCX2 NM_016378 21.33 TAF7L NM_024885 1.42
PHF6 NM_032458 21.32 COL4A5 NM_033381 1.52
NCRNA00183 NR_024582 21.31
Y-chromosome
USP9Y NM_004654 105.11 CYorf15B BC035312 29.10
ZFY NM_003411 58.63 UTY NM_182660 23.68
TTTY15 NR_001545 35.53 NLGN4Y NR_028319 19.66
EIF1AY NM_004681 35.11 NCRNA00185 NR_001544 19.01
CYorf15A NM_001005852 32.75 KDM5D NM_004653 14.19
Fold-change indicates male/female expression value (positive values, for male-biased genes) and their negative inverse (negative values, for female-biased genes).
Y-chromosome genes listed are those with an expression ratio .10.
doi:10.1371/journal.pone.0023506.t001
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Gene Symbol
Alternate gene
names Fold-change
Microarray
p-value
Composite array
score
Agreement score of
4 populations
(p,0.05)
Agreement score of
9 hybrids
ZFX 21.89 0.00E+00 16 4 9/9
PNPLA4 21.71 0.00E+00 16 4 9/9
KDM6A UTX 21.66 0.00E+00 16 4 9/9
HDHD1A 21.62 0.00E+00 16 4 8/9
RPS4X * 21.48 0.00E+00 16 4 9/9
EIF1AX 21.46 0.00E+00 16 4 9/9
KDM5C JARID1C 21.41 0.00E+00 16 4 9/9
ZRSR2 * 21.18 1.52E221 16 4 N/A
FUNDC1 21.11 7.28E217 16 4 8/9
DDX3X 21.16 1.18E214 16
a 49 / 9
UBA1 UBE1 21.12 1.11E210 14 4 9/9
EIF2S3 21.17 1.28E207 13 4 9/9
USP9X 21.12 7.20E205 12 4 9/9
PRKX 21.07 NS 13 4 7/9
CDK16 PCTK1 1.01 NS 9 4 7/7
Listed are the top 15 genes that account for almost all of the differences in gene expression between males and females in lymphoblastoid cell lines [7]. Fold-change
indicates magnitude and direction of sex-bias in expression, as in Table 1. The last two columns represent the occurrences of escape from X-inactivation for the
indicated gene in a lymphoblastoid cell line study across 4 populations [7] and in a fibroblast cell hybrid study carried out in 9 hybrids [8]. NS, not significant. Two of the
genes listed here (*) are not listed in Table 1 because their microarray probes have more than one hit in the human genome.
a- A second microarray probe for DDX3X exhibited a composite array score of 15 (Table S2A).
doi:10.1371/journal.pone.0023506.t002
Table 3. Sex-biased RefSeq genes on chromosome 19 (fold-change. |1.15| and composite array score $14).
Gene
Symbol*
Gene
Accession
Fold-
Change
Sex-
specificity Gene Symbol
Gene
Accession Fold-ChangeSex-specificity
ZNF382 NM_032825 1.35 M REEP6 NM_138393 21.15 F
LOC100128439 BC032415 1.34 M APOC4 NM_001646 21.18 F
ZNF682 NM_033196 1.31 M NFIX NM_002501 21.19 F
ZNF544 NM_014480 1.27 M SLC35E1 NM_024881 21.20 F
ZNF563 NM_145276 1.26 M CCDC123 NM_032816 21.20 F
RTN2 NM_206901 1.25 M ZNF766 NM_001010851 21.24 F
MAST1 NM_014975 1.25 M KANK2 NM_015493 21.25 F
ACER1 NM_133492 1.22 M GRLF1 NM_004491 21.25 F
ZNF28 NM_006969 1.21 M SIGLEC11 NM_052884 21.27 F
ANGPTL4 NM_139314 1.21 M RAD23A NM_005053 21.31 F
ZNF566 NM_032838 1.21 M CYP2B7P1 AK307933 21.36 F
ZNF542 NR_033418 1.20 M RAB3A NM_002866 21.37 F
TLE2 NM_003260 1.20 M LDLR NM_000527 21.42 F
ZNF829 NM_001171979 1.20 M PEG3 NM_006210 21.50 F
DOT1L NM_032482 1.19 M
ZNF549 NM_153263 1.17 M
ZNF329 NM_024620 1.17 M
ZNF8 NM_021089 1.17 M
DPY19L3 NM_207325 1.15 M
*Gene symbols shown in bold identify 13 ZNF genes; an additional 6 ZNF genes (5 male-biased) show sex biased expression when the composite array score threshold is
relaxed to 13 (see text).
doi:10.1371/journal.pone.0023506.t003
Sex Differences in Human Liver
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23506male-biased genes identified in our study were significantly
enriched in the male-biased gene set that we identified in the
465 liver study, with a normalized enrichment score (NES)=2.8
and an enrichment p-value=0. Similarly, the 558 female-biased
genes identified in our study were significantly enriched in the
corresponding female-biased genes from 465 dataset (NES=2.5,
p-value=0). Furthermore, a Pearson correlation coefficient of 0.64
was determined for the 753 male/female log2-expression ratios of
the two array datasets; this correlation exceeds the average
correlation of 0.48 that we measured within the 465 liver dataset,
based on permutation testing using random subsets of the 465
arrays (see Methods). Thus, our results show a good overall
correlation with microarray results using a distinct microarray
platform and an independent human liver cohort. Furthermore,
303 of the 753 common transcripts (40%) show a sex difference at
p,0.05 in the 465 liver set, with 256 of the 303 genes showing the
same sex-bias as seen in our 224 liver data set (84%; 76 male-
biased genes and 180 female-biased genes), validating the sex-
specificities of these genes. The finding of differences in sex bias for
some individual genes in these two studies is not unexpected, given
the differences in how the two studies were carried out (e.g.,
collection of fresh surgical samples at a single center in our study,
Figure 2. Heat map showing the male/female expression fold-change on each of 16 arrays for 45 sex-biased genes involved in
chromatin remodeling and epigenetic modification. Blue indicates female-biased expression and red indicates male-biased expression, as
shown in the linear color bar scale at top, left.
doi:10.1371/journal.pone.0023506.g002
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and amplified at different points in time for the 465 liver dataset,
different microarray platforms and probes used in each study,
different tissue acquisition and storage protocols, criteria for RNA
quality, etc.). Importantly, DAVID analysis of the 180 female-
biased genes validated in the 465 liver study showed that lipid
metabolism is a top functional cluster (Table S3D, S3E), the terms
of which include all four GWAS-associated lipid metabolism/
cardiovascular disease studies mentioned above [24,43,44,45].
Taken together, these findings provide strong independent support
for our major conclusion that human liver shows enrichment for
sex-biased genes affecting lipid metabolism and cardiovascular
disease.
Comparison to genes that show sex-dependent
expression in mouse and rat liver
Of the 1,249 genes showing sex-biased expression in human
liver, 434 of 879 mouse orthologs showed sex-biased expression in
mouse liver; similarly, 158 of 755 rat orthologs showed sex-biased
expression in rat liver (Table S5A–S5C). Pituitary GH is the
primary regulator of sex-dependent gene expression in mouse and
rat liver [14,28], including 75–77% of the sex-biased genes
common to human and either mouse or rat liver, based on their
responses to hypophysectomy (Table S5A–S5C). Gene Ontology
analysis of these pituitary-dependent genes revealed top enriched
functional terms associated with lipid metabolism, involving 41
genes in mouse and 33 genes in rat (Table S5D–S5E and and
Table S2F), 21 of which are common to all three species (Table
S2F). For those 87 genes that show sex-biased expression in all
three species, 71 respond to hypophysectomy in mouse and 67
respond in rat (Table S5B and Table S5C). Lipid metabolism-
associated terms are also the most significantly enriched in the 87
common sex-biased genes (Table S5F). Indeed, of the four sex-
biased human liver genes directly linked to monogenic disorders of
lipid metabolism, three show sex-biased gene expression in mouse
liver (Apoa5, Abca1, Lipc), and in all three cases ablation of pituitary
Table 4. Top biological functions and pathways affected by genes showing sex differences in human liver determined by
Ingenuity Pathway analysis.
A. Top Biological Functions:
1. Molecular and Cellular Functions
Name p-value range No. sex-biased genes
Lipid Metabolism 1.03E-04–4.84E-02 42(81*)
Small Molecule Biochemistry 1.03E-04–4.84E-02 68
Molecular Transport 5.52E-04–2.47E-02 15
Cell Morphology 7.65E-04–4.84E-02 12
Gene Expression 1.30E-03–4.84E-02 94
2. Diseases and Disorders
Name p-value range No. sex-biased genes
Cardiovascular Disease 2.56E-05–4.84E-02 164(185**)
Genetic Disorder 2.62E-05–5.00E-02 444
Endocrine System Disorders 4.51E-05–3.04E-04 171
Metabolic Disease 4.51E-05–4.84E-02 183
Neurological Disease 4.97E-04–3.58E-02 252
B. Top Canonical Pathways
Name p-value No. sex-biased genes
TR/RXR Activation 5.12E-04 13
PTEN Signaling 7.16E-04 13
Cyanoamino Acid Metabolism 3.94E-03 5
Fructose and Mannose Metabolism 4.73E-03 8
Arachidonic Acid Metabolism 6.20E-03 13
C. Top Tox Functions
Name p-value No. sex-biased genes
TR/RXR Activation 3.60E-04 13
Aryl Hydrocarbon Receptor (AhR) Signaling 6.24E-03 15
PXR/RXR Activation 1.66E-02 8
Cytochrome P450 Panel-Substrate is a Xenobiotic 1.86E-02 4
Positive Acute Phase Response Proteins 2.43E-02 5
*An additional 39 genes associated with lipid-related processes were identified based on functional terms collected by DAVID analysis.
**An additional 21 genes associated with cardiovascular disease were identified by querying against the Ingenuity Pathway disease database.
doi:10.1371/journal.pone.0023506.t004
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expression in female mouse liver (Table S5B).
Non-synonymous versus synonymous substitution rates
in sex-biased genes
Male-biased genes tend to evolve rapidly in protein-coding
regions in both Drosophila [46] and primate brain [47]. To
determine whether genes showing sex-biased expression in liver
might also evolve rapidly, we compared the ratio of non-
synonymous (amino acid-changing) to synonymous substitutions,
dN/dS. Figure 5 shows that dN/dS ratios for human-mouse
orthologs are significantly higher for both male-biased and female-
biased genes than for non-sex-biased genes. In other systems,
male-biased genes have a higher dN/dS ratio than female-biased
genes [46,47], however, in our data, the median dN/dS ratio for
male-biased genes was not significantly higher than for female-
Figure 3. Association of sex-biased genes with lipid metabolism. (A) Heat map of 55 sex-biased genes associated with lipid metabolism with
the 23 functional terms identified by DAVID analysis whose enrichment p-values are ,1E-5. Each row represents a functional term and each column
represents a gene, as marked at the top. Red, female-biased genes; blue, male-biased genes, with greater color intensity used to indicate genes with
higher composite array scores, as shown in the color bar scale. Red asterisks mark 8 genes involved in polygenic dyslipidemia and cardiovascular
disease as determined by GWAS [24,45]. See Table S3B for a complete listing of 81 genes associated with lipid metabolism and the 57 corresponding
functional terms. (B) Top network associated with sex-biased genes involved in lipid metabolism, as determined by Ingenuity Pathway Analysis. Other
top networks are shown in Fig. S4.
doi:10.1371/journal.pone.0023506.g003
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ratios in sex-biased gene comparisons between rat and human
liver but did not achieve statistical significance due to the small
number of common sex-biased genes in these two species.
Discussion
Sex differences in liver gene expression have been widely
studied in rat and mouse models, where they have a major impact
on hepatic physiology, inflammatory responses, diseased states,
and the metabolism of steroids, drugs and environmental
chemicals. However, little is known about sex-dependent gene
expression in human liver, which could be of substantial biological
and medical importance. Here, we report a comprehensive
analysis of human liver sex differences based on a large panel of
surgical tissue samples. More than 1,200 genes showing sex-biased
expression are identified. Notably, several of the human hepatic
sex-biased genes identified here have been previously associated
with cardiovascular disease risk, with females characterized by a
sex-biased expression profile consistent with their lower risk of
coronary artery disease. Comparing our results with studies in the
mouse, we find that half of the human-mouse orthologs also show
sex-biased expression in mouse liver, although many genes reverse
their sex bias. Those genes that show the same sex-bias in human
and mouse liver are shown to evolve more rapidly than non-sex-
biased genes. These findings provide novel insights into human
hepatic sex differences important for processes such as drug
metabolism and pharmacokinetics, and could help explain sex
differential risk of coronary artery disease.
Sex differences in pathophysiology and disease risk characterize
many tissues, including liver [48]. Large numbers of sex-
dependent genes have been identified in mouse and rat liver,
where male-female differences range from ,2-fold to .1,000-fold
[49]; however, previous global expression studies in human liver
[19] and other tissues [38,47,50,51] have been very limited in
scope and lack sufficient statistical power to identify large numbers
of sex-biased genes. The present study addressed this problem
using a large panel of human livers and a pooling strategy that
gives high statistical power, which enabled us to quantify sex
differences in expression as low as 15%. Such differences can be
Figure 4. Heat map showing the male/female expression fold-change on each of 16 arrays for 20 ADME and 10 ADME-related genes
that show sex-bias in human liver. Blue indicates female-biased expression and red indicates male-biased expression, as shown in the linear color
bar scale at top, left.
doi:10.1371/journal.pone.0023506.g004
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particular when multiple genes within a pathway are affected [52].
Using this approach, we identified many human hepatic genes that
show sex-biased expression, affecting a broad range of biological
processes important for human physiology and homeostasis,
including lipid and drug metabolism. Key findings were validated
by comparison to results reported for a 465 liver dataset [33],
where an analysis of sex differences had not previously been
carried out.
Male-biased zinc finger clusters on chromosome 19
We identified 19 sex-dependent ZNF genes on chromosome 19,
16 of which showed male-biased expression and all but one of
which map to 6 of 11 previously defined C2H2 type ZNF gene
clusters on this chromosome (Fig. 1B; also see Table 3 and Table
S2C) [40]. Notably, 15 of the 16 male-biased ZNFs contain a
KRAB domain, which confers transcription repression [53],
suggesting these ZNFs might target other liver-expressed genes
and thereby contribute to female-biased gene expression. One of
the female-biased ZNF genes, PEG3, is maternally imprinted, i.e.,
only the paternal allele is expressed [54], and is involved in
signaling pathways regulated by NFKB, p53, tumor necrosis
factor, and BAX [55]. PEG3 DNA methylation is controlled by the
transcription factor YY1 [56], which also showed female bias
(p=3.52E-11, composite array score=15 and female/male
ratio=1.14). It will be interesting to determine whether sex
differences characterize the epigenetic modifications surrounding
the clusters of male-biased ZNFs on chromosome 19, in particular
the six genes in ZNF cluster 11 (Table S2D).
Epigenetics and sex differences in human liver
Epigenetic modifications play a critical role in sex differentia-
tion, and recent evidence indicates a close association between
gonadal sex steroids and both DNA and histone methylation
[4,10]. For example, CpG methylation and the histone modifica-
tion pattern of the Esr1 promoter is sexually dimorphic in mouse
brain [57,58], where sex steroid exposure can impart sex
differences in DNA methylation [4]. KDM lysine demethylases
may also contribute to sexual dimorphism via sex differences in
their expression and/or intracellular distribution [4,10,11,12].
Presently, we found that sex-biased genes were enriched in
processes related to chromosome organization and modification,
suggesting a role for genes such as the sex-linked JMJC domain
histone demethylases (X-chromosome: KDM5D, UTY; Y-chromo-
some: KDM5C, KDM6A) [59,60] in the establishment and/or
maintenance of liver sexual dimorphism. Female-biased genes
active in epigenetic modification, including MLL and KDM6A,
may be key trans-regulators of HOX cluster gene expression
[61,62,63], which is important for pattern formation during
development. Notably, 22 genes associated with pattern specifica-
tion processes showed female-biased expression, including two
HOX genes (HOXB3 and HOXD11) (Table S3A). Genes such as
these could contribute to sex-biased differentiation of male and
female liver during development.
Sex-biased expression of hepatic drug-metabolizing
enzymes
Sex differences in drug metabolism and pharmacokinetics can
lead to sex differences in drug action and drug response, and have
been related to the expression of key CYP enzymes of phase I
(oxidative) drug metabolism [49]. Best documented is the female-
biased expression of CYP3A4 in human liver [17,18], which was
confirmed by our microarray analysis showing 29% higher
CYP3A4 expression in the female livers used in this study, a result
that was validated by quantitative PCR using the same set of livers
(30% female-biased expression; data not shown). Sex-differences in
expression or activity have been reported for several other CYP
enzymes (CYPs 1A2, 2B6, 2C9, 2D6, 2C19 and 2E1) but are not
seen consistently and remain controversial [64]. Sex-biased
expression has also been reported for certain human phase II
drug-metabolizing enzymes of the GST, UGT and ADH families
[49,65], but can vary between ethnic groups [65]. Here, using a
panel of liver samples from individuals of Western European
descent, we identified 40 drug-metabolizing enzyme genes and
other ADME or ADME-related genes that show sex-biased
expression. These include CYP1A2, CYP3A4 and CYP7A1 showing
female bias, and CYP3A5, CYP27B1, APCS, PLA1A and UGT2B15
showing male bias (Figure 4 and Table S2H). In the case of
CYP1A2, our finding of female-biased expression contradicts
findings suggesting higher expression in males based on in vivo
clearance rates of typical CYP1A2 substrates [64]. We also
observed higher expression of CYP3A5 in males, which contrasts to
the female-biased expression of CYP3A4, although we cannot
exclude a confounding effect of CYP3A5 genetic polymorphisms
[66].
Several nuclear receptors have been implicated as regulators of
CYPs and other drug-metabolizing enzyme genes; these include
HNF4A (NR2A1) and the xenobiotic-activated nuclear receptors
CAR, PXR, and PPARA, which respond to a wide range of
xenochemicals and induce the expression of CYP2B, CYP3A, and
CYP4A and CYP7A genes, respectively [67,68]. Steroid hormone-
dependent responsiveness has been reported in rodent models for
these receptors, as well as for AhR, the receptor/transcription
factor that induces CYP1 and other genes upon binding certain
drugs and environmental chemicals [69]. HNF4A and PPARA both
showed significant female-biased expression in human liver (Table
S2A). HNF4A is a master regulator of gene expression in human
liver [70,71], and its female bias could contribute to the
predominance of female-biased over male-biased genes (70% of
Figure 5. Non-synonymous versus synonymous substitutions
in human and mouse sex-biased genes. Shown is a box plot of dN/
dS ratios of common male-biased, female-biased and non-sex-biased
genes between human and mouse. Numbers in parenthesis indicate the
number of genes in each set. Common sex-biased genes that show
consistent sex-bias in both human and mouse liver (MM and FF) had
dN/dS ratios significantly higher than non-sex-biased genes (median of
male-biased genes=0.128, median of female-biased genes=0.104,
median of non-sex-biased genes=0.074). Permutation p-values are
indicated by **p,0.01 and ***p,0.001. The median dN/dS ratio for
common male-biased genes was not significantly different than for
female-biased genes (permutation p-value=0.11).
doi:10.1371/journal.pone.0023506.g005
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nuclear receptor pathways are among the top pathways associated
with sex-biased gene expression in human liver, including TR/
RXR/LXR activation, AhR signaling, ER signaling, and PPAR
signaling (Table 4B, Table 4C and Table S4B). Collectively, the
observed sex differences in expression of drug metabolizing
enzymes and other ADME genes may help explain clinical
differences in drug response, including adverse drug reactions,
which are frequently higher in females than in males [49].
Association of sex dimorphism in lipid metabolism and
heart disease
Dyslipidemia is a key risk factor in developing heart disease,
whose lower incidence in women [22,23] has been related to sex
differences in lipid profiles [20,21]. Thus, women typically have a
more favorable lipid profile, with lower circulating levels of LDL
(low density lipoprotein), higher levels of HDL, and lower
triglyceride levels compared to men [20,21]. These clinical
observations are consistent with our finding that, of 8 sex-biased
genes near loci associated with polygenic dyslipidemia and
coronary heart disease [24,45] (Table S2F), loss-of-function
mutations in four genes result in monogenic disorders of lipid
metabolism [72,73,74,75,76]. Strikingly, the sex-bias of these four
genes (LDLR, APOA5 and ABCA1, all more highly expressed in
female liver; and LIPC, more highly expressed in male liver) is
consistent with the more favorable lipid profile and lower
cardiovascular disease risk profile of women. For example, familial
hypercholesterolemia is induced by inherited defects in LDL
receptor (LDLR), which disrupts hepatic control of circulating
LDL-cholesterol [74]. Inherited APOA5 deficiency is associated
with severe hypertriglyceridemia [73] and, in another study [77],
serum APOA5 concentrations were elevated in females compared
to males, were negatively correlated with trigyceride concentra-
tions in females, and were positively correlated to HDL-cholesterol
levels in both males and females. Mutations in ABCA1 have been
associated with Tangier’s disease and familial HDL deficiency
[76], and individuals with high HDL-cholesterol levels have
homozygous deficiencies of LIPC [75]. The increased expression
of LDLR, APOA5 and ABCA1 that we observed in female liver,
together with the lower expression of LIPC, can thus be expected
to result in lower levels of LDL, lower triglycerides and higher
levels of HDL in females, a lipid profile that predicts a lower risk of
cardiovascular diseases. Other female-biased genes that we
speculate contribute to the more favorable lipid metabolic profile
of females include CYP7A1, encoding cholesterol 7a-hydroxylase,
which catalyzes a key regulated step in the conversion of hepatic
cholesterol to bile acids and is a target of bile acid sequestrants
used to induce CYP7A1 in the treatment of hypercholesterolemia
[78], and PPARA, which is activated by hypolipidemic fibrate
drugs [79]. CYP7A1 and PPARA both showed ,40% higher
expression in female than male liver (Table S2A).
The favorable lipid profile of women has been ascribed to the
protective effects of estrogen during a woman’s reproductive years,
although other factors, such as GH, which plays a major role in
determining sex differences in rodent liver, could also be a factor.
Clinical studies suggest that estrogen reduces LDL-cholesterol
levels and increases HDL-cholesterol levels in post-menopausal
women [80,81]. Furthermore, estrogen deficiency may decrease
rates of triglyceride metabolism by down-regulating transcription
factors such as PPARA [82], a key regulator of lipid metabolism.
The likely beneficial effects of the higher expression of PPARA seen
here for female liver include increases in HDL levels, decreases in
triglycerides via increased beta-oxidation, induction of ABCA1,
increases in insulin sensitivity, and protection from atherosclerosis
[83]. Notably, follicle-stimulating hormone (FSH) and luteinizing
hormone (LH), which act synergistically in reproduction [84], are
among the hub components in the top networks affected by the
1,249 sex-biased genes, as well as by the subset of 81 lipid-
associated genes (Figure S4A, S4B, Table S4C). The relationship
between FSH, LH and lipid metabolism suggested by these
networks is consistent with a report that increased levels of FSH
and LH in men with coronary artery disease are associated with
increased levels of HDL-cholesterol, suggesting these hormones
exert cardio-protective effects [85]. Another study reported,
however, that elevated basal FSH was associated with unfavorable
lipid levels (high LDL) and increased cardiovascular risk in normal
cycling women [86].
GH regulation of sex-biased gene: species similarities and
species differences
A large majority of the sex differences in mouse and rat liver are
regulated by GH [49], and correspondingly, a large fraction (75–
77%) of the mouse and rat orthologs of sex-biased genes of human
liver were characterized by pituitary hormone-dependence in
mouse and/or rat liver; these include three of the four sex-biased
human liver genes directly linked to monogenic disorders of lipid
metabolism (Apoa5, Abca1, Lipc). These findings suggest that GH
might also regulate the corresponding sex-biased genes in human
liver, and by extension, the lipid metabolic processes and
cardiovascular disease risks associated with these genes. Indeed,
clinical studies indicate GH is an important determinant of lipid
profiles in both healthy adults and GH-deficient patients [87], and
clinically significant sex differences in GH responsiveness have
been reported [88,89]. Consistent with this proposal, two
transcription factors implicated in the sex-dependent actions of
GH in mouse and rat liver (CUX2, ONECUT2) [14,28], also
show sex-biased expression in human liver. GH can also exert sex-
dependent effects on drug metabolism in humans [90], most likely
through its effects on human hepatic CYP3A4 and other drug-
metabolizing enzymes [49], several of which show strong GH-
regulated hepatic sex differences when introduced into transgenic
mice [91,92]. The proposed role of GH in the regulation of sex-
biased hepatic lipid and drug metabolism is an important area for
further research.
Finally, species differences were apparent between human,
mouse and rat, both with regards to the sex-specificity of
individual genes (Table S5A) and the magnitude of sex differences
(Table S5B and Table S5C). For example, of the 340 genes
showing female-biased expression in human liver that also show
sex-biased expression in mouse liver, 230 are more highly
expressed in female mouse liver while 110 are more highly
expressed in male mouse liver (Table S5A). At least some of these
differences may be indicative of underlying species differences in
associated physiological functions, such as the opposite sex-
specificity of HDL-cholesterol levels in mice (male.female) [93]
compared to humans [20]. Furthermore, the magnitude of sex
differences in human liver is small (mostly ,2-fold) compared to
mouse and rat liver, where sex-differences in expression can range
up to 1,000-fold.
In summary, this is the first comprehensive study of gene
expression differences between sexes in human liver. More than
1,200 genes showing significant sex differences in expression and
affecting diverse physiological functions were identified, with
overall patterns and the key finding of sex differences in genes
important for lipid metabolism and cardiovascular disease risk
validated by analysis of an independent human liver cohort. These
findings increase our understanding of sex differences in human
liver at the molecular level and provide important insights into our
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PLoS ONE | www.plosone.org 13 August 2011 | Volume 6 | Issue 8 | e23506understanding of clinical traits and drug responses. However,
several limitations should be noted. First, the present analysis is
based on liver samples from individuals of Western European
descent, and needs to be validated for other cohorts, including
livers representing other ethnic and racial groups. Second, the
present study utilized fresh surgical specimens of non-tumorous
tissue, primarily obtained from patients having primary liver
tumors removed; however, there is no indication of sex-differences
between such non-tumorous liver samples and livers obtained from
non-tumor bearing donors, a supposition that is supported by our
validation of key results using a second human liver cohort,
primarily comprised of cancer-free post-mortem tissues. Third, the
results presented are entirely based on microarray data, and it
remains to be established to what extent the observed sex
differences in gene expression will be indicative of sex differences
at the protein level and at the level of biological activity. However,
the striking consistency between our findings of sex-biased genes
affecting lipid metabolism and cardiovascular disease risk and
related clinical observations, discussed above, suggest that, at least
in this area, our gene expression findings are functionally relevant.
Finally, the present findings did not investigate sex-differences in
gene expression and function that could arise from other, non-
RNA-based mechanisms, such as translational regulation, protein
stability and via post-translation modifications that alter biological
function and activity. Further studies of sex-biased human hepatic
genes at the genetic, regulatory and functional level can be
expected to increase our understanding of their role in hepatic
physiology and diseases states.
Supporting Information
Figure S1 Distribution of male- and female-biased
genes on each chromosome. (A) sex-biased genes are plotted
against the male/female (M/F) log2 ratio. The length of the x-axis
for each chromosome is proportional to the number of sex-biased
genes. The three red lines represent male/female |fold-
change|=1.15, 0 and 21.15, respectively. (B) The log2 M/F
expression ratios for sex-biased genes were plotted along the X-
chromosome using coordinates based on hg18.
(TIF)
Figure S2 Distribution of male- and female-biased
genes on each chromosome based on less stringent
levels of significance than shown in Fig. 1A. Shown along
the Y-axis are the numbers of male- and female-biased genes on
each chromosome based on the combined criteria of |fold-
change|.1.15 and either composite array score $13 (A) or
composite array score $12 (B). Numbers at the top of each bar
indicate the ratio of the number of female-biased genes to male-
biased genes on each chromosome. Asterisks indicate the
significance of the sex ratio based on Chi-square tests (*p,0.05;
** p,0.01; ***p,0.001; red asterisks indicate significant enrich-
ment of female-biased genes and blue asterisks indicate significant
enrichment of male-biased genes).
(TIF)
Figure S3 Functional cluster enrichment analysis illus-
trating the biological functional terms enriched among
sex-biased genes. Shown are enriched functional terms
associated with female-biased genes (A) or in male-biased genes
(B). Statistically over-represented functional terms were determined
by comparing the incidence of a functional term within the input
gene list (observed, blue bar) to the incidence of that functional term
among the entire human genes that have functional annotations
collected by DAVID analysis (expected, red bar). Fisher’s exact test
was used to determine a p-value for each term.
(TIF)
Figure S4 Top networks involving sex-biased genes
identified by Ingenuity Pathway Analysis. (A) Shows a
top network of all sex-biased genes, which is associated with
genetic disorder, reproductive system disease, cell-to-cell signaling
and interaction. (B) Shows a top network of subset of sex-biased
genes involved in lipid metabolism, which is associated with DNA
replication, recombination, and repair, cell death and hepatic
system disease. Green nodes indicate female-biased genes, and red
nodes represent male-biased genes. Also see Fig. 3B.
(TIF)
Table S1 (A) Summary of patient data for livers included in this
study, and (B) listing of 16 male and 16 female RNA pools used for
microarray analysis.
(XLS)
Table S2 (A) Lists of all (1249) sex-biased genes based on criteria
|fold-change|.1.15 and composite array score .14 including
M/F expression ratio, p-value and composite array score. (B) An
additional 1041 sex-dependent genes (411 male liver predomi-
nantly expressed genes and 630 female liver predominantly
expressed genes) based on criteria composite array score .=12,
p,0.005 and |fold-change|.1.15. (C) 19 sex-dependent zinc
fingers on chromosome 19 based on criteria: composite array score
.=13, p,0.005 and |fold-change|.1.15. (D) 158 sex-biased
genes involved in transcription. (E) 45 sex-biased genes associated
with chromatin organization and modification. (F) 81 sex-biased
genes associated with lipid metabolism. (G) 185 sex-biased genes
associated with cardiovascular disease. (H) 40 sex-biased ADME
and ADME-related genes.
(XLS)
Table S3 (A) functional clusters enriched (enrichment score
.1.5) for sex-biased genes. (B) 57 lipid-associated functional terms
and 81 lipid-associated genes.
(XLS)
Table S4 Biological functions (A), canonical pathways (B) and
networks (C) associated with human liver sex-biased genes
identified by Ingenuity Pathway analysis.
(XLS)
Table S5 (A) Comparison of genes showing sex-biased expres-
sion in human, mouse and rat liver, and effect of hypophysectomy
in mouse and rat. (B) List of 434 genes that show sex-biased
expression in both human and mouse liver. (C) List of 158 genes
that show sex-biased expression in both human and rat liver. (D–F)
Listings of enriched functional clusters identified by DAVID
(enrichment score .1.5) for genes that show sex-biased expression
in human liver and either mouse liver (D) or rat liver (E) or mouse
and rat liver (F), and where expression of the sex-biased mouse and
rat genes is altered by hypophysectomy.
(XLS)
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